B+
Bull case
25%
Probability
Target price
$30.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
CBIO
Crescent BiopharmaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+56.8
Score
AI commentary
Sentiment is cautiously constructive but still speculative. The February 26, 2026 update gave Crescent a clearer operating roadmap: ASCEND has started, CR-002 is aiming for a mid-2026 IND, more trials are planned in 2026, and management says cash of $213.2 million should fund operations into 2028 [#PR-2026-02-26] [#8-K-2026-02-26]. But forward visibility remains limited because the key proof-of-concept data do not begin until Q1 2027, and the deterministic score bundle still points to neutral-to-soft near/intermediate returns rather than a strong positive setup.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystCR-002 IND submission target in mid-2026High impact
Management said Crescent is on track to submit an IND for CR-002 in mid-2026 to support a Phase 1/2 trial in solid tumors in the second half of 2026; hitting that filing would be the next concrete pipeline de-risking step for a company still early in clinical execution [#PR-2026-02-26] [#8-K-2026-02-26].
2026-09-30eventAdditional 2026 trial starts across CR-001/CR-002High impact
Crescent said the ASCEND Phase 1/2 trial for CR-001 is underway, three additional trials are expected to initiate in 2026, and the first Phase 1/2 ADC combination trial with CR-001 is expected in the second half of 2026; any slip here would likely pressure sentiment because the current thesis rests on milestone delivery rather than revenue [#PR-2026-02-26].
2027-03-31catalystInitial proof-of-concept data beginning Q1 2027High impact
The clearest value-creation hook is management's guidance for multiple clinical data readouts beginning in Q1 2027, including initial ASCEND safety, PK/PD, and preliminary antitumor activity; positive early data could materially re-rate shares, but this remains low-visibility and high-risk today [#PR-2026-02-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology